Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
19.20
Nov 17 • 3:59 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
660.27M
Enterprise Value
519.56M
Income
-50.45M
Sales
0.00M
Book/sh
4.93
Cash/sh
4.09
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
13
IPO
Feb 04, 2022
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
3.89
P/C
4.69
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
9.92
Current Ratio
9.92
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-1.86
EPS next Y
-1.70
EPS next Q
-0.37
EPS this Y
-54.04%
EPS next Y
16.64%
EPS next 5Y
-14.86%
EPS past 3/5Y
4.25% -340.28%
Sales past 3/5Y
- -
EPS Y/Y TTM
-41.15%
Sales Y/Y TTM
-
EPS Q/Q
-134.38%
Sales Q/Q
-
Insider Own
35.16%
Insider Trans
0.52%
Inst Own
37.57%
Inst Trans
46.73%
ROA
-57.20%
ROE
-66.98%
ROIC
-39.84%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-1.92%
SMA50
-5.90%
SMA200
25.56%
Trades
Shs Outstand
25.68M
Shs Float
22.30M
52W High
29.27 -34.42%
52W Low
5.77 232.76%
Volatility
5.67% 8.26%
ATR (14)
1.48
RSI (14)
45.90
Beta
-0.21
Rel Volume
0.00
Avg Volume
208.68K
Volume
0
Perf Week
-8.92%
Perf Month
1.37%
Perf Quarter
-17.70%
Perf Half Y
86.41%
Perf YTD
154.30%
Perf Year
215.79%
Perf 3Y
134.15%
Perf 5Y
-
Perf 10Y
-
Prev Close
19.20
Price
19.20
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$35.40
Implied Upside
+84.4%
Analysts4incl. previous ratings
Rating Distribution4 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 24, 2026Initiated
CCantor Fitzgerald
Overweight
Apr 02, 2025Initiated
MMaxim Group
Buy$17-11.5%
Mar 17, 2025Initiated
LLaidlaw
Buy$19-1.0%
Jul 13, 2022Initiated
LLadenburg Thalmann
Buy$21+9.4%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mosseri Marlio Charles10% OwnerJun 30 '26Buy18.3250,000916,0003,186,576Jul 01 01:41 PM
BENTSUR RONChairman & CEOJun 30 '26Buy20.0012,500250,0003,688,424Jul 01 01:39 PM
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its product pipeline includes NXP800 and NXP900. The company was founded by Ronald E. Bentsur, Enrique Poradosu, and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.
Co-FounderMr. Ron Bentsur M.B.A.
Co-FounderDr. Enrique Poradosu Ph.D.
Co-FounderMr. Shay Shemesh
Vice President of FinanceMr. Michael Carson CPA